Bibliography
Found 48 results
Filters: Keyword is Adult and Author is Letendre, Scott [Clear All Filters]
Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States. Clin Infect Dis. 2018 ;67(8):1182-1190.
. Impaired insulin sensitivity is associated with worsening cognition in HIV-infected patients. Neurology. 2019 ;92(12):e1344-e1353.
Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol. 2013 ;19(4):393-401.
Insulin-like growth factors and related proteins in plasma and cerebrospinal fluids of HIV-positive individuals. J Neuroinflammation. 2015 ;12:72.
. A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology. 2013 ;81(17):1492-9.
Lithium improves HIV-associated neurocognitive impairment. AIDS (London, England) [Internet]. 2006 ;20:1885-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16954730
. Markers of macrophage activation and axonal injury are associated with prospective memory in HIV-1 disease. Cognitive and Behavioral Neurology: Official Journal of the Society for Behavioral and Cognitive Neurology [Internet]. 2006 ;19:217-21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17159619
. Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol. 2012 ;18(6):511-20.
Modifications in acute phase and complement systems predict shifts in cognitive status of HIV-infected patients. AIDS. 2017 ;31(10):1365-1378.
Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology. 2013 ;80(15):1415-23.
. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis. 2015 ;60(3):473-80.
Neurocognitive impairment in HIV-infected individuals with previous syphilis. Int J STD AIDS. 2013 ;24(5):351-5.
Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol. 2011 ;33(5):505-22.
Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. The Journal of Infectious Diseases [Internet]. 2007 ;196:361-70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17597450
Peripheral Blood Mitochondrial DNA Copy Number Obtained From Genome-Wide Genotype Data Is Associated With Neurocognitive Impairment in Persons With Chronic HIV Infection. J Acquir Immune Defic Syndr. 2019 ;80(4):e95-e102.
. Personalized Risk Index for Neurocognitive Decline Among People With Well-Controlled HIV Infection. J Acquir Immune Defic Syndr. 2017 ;76(1):48-54.
. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. Journal of Neurovirology [Internet]. 2006 ;12:100-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16798671
. Relationship of CSF leukocytosis to compartmentalized changes in MCP-1/CCL2 in the CSF of HIV-infected patients undergoing interruption of antiretroviral therapy. Journal of Neuroimmunology [Internet]. 2006 ;179:180-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16901548
. Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother. 2012 ;56(4):1985-9.
Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother. 2010 ;54(12):5156-60.
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 ;65(1):65-70.
White matter damage, neuroinflammation, and neuronal integrity in HAND. J Neurovirol. 2019 ;25(1):32-41.